SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Rallybio Corporation (RLYB) has a negative trailing P/E of -4.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 2.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -20.75%, forward earnings yield 47.39%.
Criteria proven by this page:
- VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -4.8); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -20.75%).
- Forward P/E 2.1 — analysts expect a return to profitability with estimated EPS of $3.92 for FY2029.
- Trailing Earnings Yield -20.75% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 47.39% as earnings recover.
Overall SharesGrow Score: 49/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — RLYB
Valuation Multiples
P/E (TTM)-4.8
Forward P/E2.1
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.75
P/S Ratio50.49
EV/EBITDA-0.4
Per Share Data
EPS (TTM)$-1.70
Forward EPS (Est.)$3.92
Book Value / Share$10.97
Revenue / Share$0.16
FCF / Share$-5.64
Yields & Fair Value
Earnings Yield-20.75%
Forward Earnings Yield47.39%
Dividend Yield0.00%
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-17.8 |
0.00 |
18.60 |
0.00 |
- |
| 2020 |
-11.9 |
-0.10 |
2.31 |
0.00 |
- |
| 2021 |
-6.5 |
-0.29 |
1.75 |
0.00 |
- |
| 2022 |
-3.1 |
-0.07 |
1.23 |
0.00 |
- |
| 2023 |
-1.3 |
0.11 |
0.91 |
0.00 |
- |
| 2024 |
-0.7 |
0.03 |
0.68 |
65.73 |
- |
| 2025 |
-3.4 |
0.04 |
0.53 |
36.02 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.55 |
$0.00 |
$-17.63M |
- |
| 2020 |
$-0.78 |
$0.00 |
$-24.93M |
- |
| 2021 |
$-1.46 |
$0.00 |
$-47.01M |
- |
| 2022 |
$-2.09 |
$0.00 |
$-66.49M |
- |
| 2023 |
$-1.84 |
$0.00 |
$-74.56M |
- |
| 2024 |
$-1.33 |
$636K |
$-57.78M |
-9084.1% |
| 2025 |
$-1.59 |
$858K |
$-8.98M |
-1046.4% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-5.40 |
$-5.40 – $-5.40 |
$80K |
$80K – $80K |
2 |
| 2027 |
$-11.52 |
$-11.52 – $-11.52 |
$87.9M |
$87.9M – $87.9M |
1 |
| 2028 |
$-3.12 |
$-3.12 – $-3.12 |
$87.5M |
$87.5M – $87.5M |
1 |
| 2029 |
$3.92 |
$3.92 – $3.92 |
$89M |
$89M – $89M |
1 |
